- Current report filing (8-K)
March 21 2012 - 5:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest event Reported): March 21, 2012
CHINA BIOLOGIC PRODUCTS, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
001-34566
|
75-2308816
|
(State or other jurisdiction of
|
(Commission File No.)
|
(IRS Employer ID No.)
|
incorporation or organization)
|
|
|
18th Floor, Jialong International Building,
19 Chaoyang
Park Road
Chaoyang District, Beijing 100125
Peoples Republic of China
(Address of Principal Executive Offices)
(+86) 10-6598-3111
Registrant's telephone number,
including area code
_______________________________________________
(Former
name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (
see
General Instruction A.2. below):
[_] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a -12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d -2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e -4(c))
Item 8.01. Other Events.
On March 15, 2012, Chao Ming Zhao, Chief Executive Officer and
President of China Biologic Products, Inc. (the "Company"), adopted a Rule
10b5-1 trading plan (the "Plan"), pursuant to which, through a broker, Mr. Zhao
will sell up to 200,000 shares of common stock of the Company over a 12-month
period. Mr. Zhao entered into the Plan as part of his personal long-term
investment strategy for asset diversification and liquidity and he will have no
control over the timing of the sales of shares of common stock under the Plan.
Any sale made
under the Plan will be publicly disclosed as required by applicable securities
laws.
The Plan was adopted in accordance with Rule 10b5-1 under the
Securities Exchange Act of 1934, as amended, and the Company's insider trading
policy. Rule 10b5-1 permits the implementation of a plan to prearrange purchases
or sales of securities by insiders if the plan is adopted at a time when the
insiders are not aware of any material, non-public information.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date: March 21, 2012
|
CHINA BIOLOGIC PRODUCTS, INC.
|
|
|
|
|
|
By:
/s/ Chao Ming
Zhao
|
|
Chao Ming Zhao
|
|
Chief Executive Officer
|
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jun 2024 to Jul 2024
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jul 2023 to Jul 2024